Exhibit 99.1

FOR IMMEDIATE RELEASE
For investor inquiries:
For press inquiries:
John Mills, ICR
Katie Brazel, FleishmanHillard
for Alimera Sciences
for Alimera Sciences
310-954-1105
404-739-0150
John.Mills@ICRINC.com
Katie.Brazel@fleishman.com


ALIMERA SCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2013 FINANCIAL RESULTS

ILUVIEN® Revenue Growth in Europe Continues

$37.5 Million Private Placement Completed to Expand ILUVIEN Commercialization

Alimera Will Host a Conference Call at 4:30 PM ET Today



ATLANTA, GA, February 27, 2014 — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2013.

“This is an exciting time for Alimera. We made significant commercial progress with ILUVIEN® during the fourth quarter of 2013 in Germany and the United Kingdom, and entered into labeling discussions with the U.S. Food and Drug Administration,” said Dan Myers, president and chief executive officer of Alimera Sciences. “We grew total revenue more than 23% on a sequential basis, primarily through sales of ILUVIEN in Germany, despite the holiday seasonality effect and market access constraints during the fourth quarter.”

“We also received positive final guidance for ILUVIEN from the U.K.’s National Institute for Health and Care Excellence, ultimately expanding patient access to ILUVIEN through the National Health Service in England and Wales. Initial shipments have been made to several National Health Service facilities, with the first patient receiving an ILUVIEN implant in January 2014,” Mr. Myers continued. “Additionally, the Scottish Medicines Consortium, after completing its assessment and review of a simple patient access scheme, accepted ILUVIEN for restricted use within the National Health Service Scotland, providing expanded access in the U.K. to patients suffering from chronic DME.”


The following information was filed by Alimera Sciences Inc (ALIM) on Thursday, February 27, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alimera Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alimera Sciences Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account